MYC and hematologic disorder: Overall, these studies may suggest MYSM1 as a drug-target for cMYC driven hematologic malignancies; and the Mysm1DN mouse strain described in our current work will allow to test whether the loss of MYSM1 DUB catalytic function can offer similar therapeutic benefits.